Bionano Genomics Inc

NASDAQ:BNGOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Contact Information

Headquarters

9640 TOWNE CENTRE DRIVE 9640 TOWNE CENTRE DRIVESAN DIEGO, CA, United States 92121

Phone

858-888-7600

Fax

858-888-7601

Executives

Independent Chairman of the Board

David Barker

President, Chief Executive Officer, Principal Financial Officer, Director

R. Erik Holmlin

Chief Financial Officer

Gulsen Kama

Chief Operating Officer

Mark Oldakowski

General Counsel, Secretary

Jonathan Dixon